May 8th is World Ovarian Cancer Day, a day to raise awareness about the disease. Ovarian cancer has the lowest survival rate of all female cancers. Learn what one Massachusetts General Hospital researcher is doing to improve diagnosis in the hopes of saving patients’ lives.

Despite advances in the early identification of some cancers, the ability to detect ovarian cancer in its early stages continues to elude researchers. Cheng Wang, PhD, a researcher and principal investigator in the MGH Vincent Center for Reproductive Biology (VCRB), is determined to change that.

Ovarian high grade serous carcinoma (HGSOC) accounts for 70 percent of epithelial ovarian cancer cases, making it the most aggressive subtype. While a majority of women are diagnosed during the late stages of the HGSOC, if it is diagnosed early and the cancer is confined, the disease is highly curable.

“Ovarian cancer is known as a ‘silent killer,’” says Wang. “For many women, before you know it, it’s too late. Women with advanced stage HGSOC have a five-year survival rate of around 30 percent. However, when HGSOC is caught early, the five-year survival rate is near 90 percent.”

The early detection project in Wang’s laboratory aims to discover key alterations – during malignant transformation of ovarian and fallopian tube cells.  These alterations could be used as biomarkers to find the cancerous cells at very early stages and ultimately predict and prevent its spread. Wang – who established his new lab in the VCRB in July 2017 –is examining what leads to the genetic or genomic alterations of the fallopian tube lining cells; why cells with these alterations become transformed, and how the transformed cells colonized in the ovary and surrounding tissues to form high grade serous ovarian cancers. “I want to know what happens behind the disease,” he says.

“I started my career as a biologist studying the female reproductive system,” Wang says. “Then, at a research fundraising event I attended, I had the opportunity to meet many ovarian cancer survivors. I realized if I changed my path of study a little bit to oncology, I might be able to use my understanding of biology to save someone’s life.”

Before joining the MGH, Wang received a grant from Colleen’s Dream Foundation – a non-profit foundation that raises awareness for ovarian cancer and supports early-detection research. The funding not only supported his research but also provided him the opportunity to spend quality time with those whose lives have been touched by ovarian cancer, including the Kenkel family from Harlan, Iowa, active fundraisers and supporters of Colleen’s Dream Foundation.

The researcher says a visit to the Kenkel’s home allowed him to establish a bond with the family who had lost their mother to ovarian cancer – and it further cemented the laboratory’s dedication to the field. Colleen’s Dream Foundation recently awarded Wang an additional grant to continue his research in the hopes of improving the chances of early detection and treatment.

“Researchers in our lab work very hard,” says Wang. “Why? Because we believe that our work will help save someone’s daughter or wife or mother.”

This post originally appeared on the Mass General website.

About the Mass General Research Institute
Research at Massachusetts General Hospital is interwoven through more than 30 different departments, centers and institutes. Our research includes fundamental, lab-based science; clinical trials to test new drugs, devices and diagnostic tools; and community and population-based research to improve health outcomes across populations and eliminate disparities in care.
Support our Research